Abuse and addiction: Crack

Revista da Associacao Medica Brasileira

Volumn 58, Issue 2, 2012, Pages 141-153

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861312296     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0104-4230(12)70173-2     Document Type: Article

References (163)

1. Carlini EA, Nappo SA, Galduróz JC. A cocaína no Brasil ao longo dos últimos anos. Rev ABP-APAL. 1993;15:121-7.
2. Dunn J, Laranjeira R. Cocaine-profiles, drug histories, and patterns of use of patients from Brazil. Subst Use Misuse. 1999;34:1527-48.
3. Dunn J, Ferri CP, Laranjeira R. Does multisite sampling improve patient heterogeneity in drug misuse research? Drug Alcohol Depend. 2001;63:79-85.
4. United Nations Office for Drug Control and Crime Prevention (UNODCCP). Global illicit drug trends 200 [online]. Vienna: UNODCCP; 2001. Available from: http://www.undcp.org/adhoc/report_2001-06.
5. Negrete JC. Cocaine problems in the coca growing countries of South America. In: Bock GR, Whelan J, eds. Cocaine: scientific and social dimensions. Ciba Foundation Symposium 166. Chichester: John Wiley & Sons; 1992. p.40-9.
6. United Nations Office for Drug Control and Crime Prevention (UNODCCP). Global illicit drug trends 2010 [online]. Vienna: UNODCCP; 2010. Available from: http://www.undcp.org/adhoc/report_2001-06-26_1/report_2001-06-26_1.pdf.
7. Noto AR, Nappo SA, Galduróz JC, Mattei R, Carlini EA. IV Levantamento sobre uso de drogas entre crianças e adolescentes em situação de rua de seis capitais brasileiras. São Paulo: Centro Brasileiro de Informações sobre Drogas Psicotrópicas (CEBRID); 1997; Universidade Federal de São Paulo; 1998.
8. o graus em 10 capitais brasileiras. São Paulo: Centro Brasileiro de Informações sobre Drogas Psicotrópicas (CEBRID); 1997.
9. Galduróz JC, Noto AR, Nappo SA, Carlini EA. I levantamento nacional sobre o uso de drogas psicotrópicas-Parte A. Estudo envolvendo as 24 maiores cidades do estado de São Paulo. São Paulo: Centro Brasileiro de Informações sobre Drogas Psicotrópicas (CEBRID), Universidade Federal de São Paulo; 2000.
10. Noto AR, Galduróz JC, Nappo SA, Fonseca AM, Carlini CM, Moura YG, et al. Levantamento nacional sobre uso de drogas entre crianças e adolescentes em situação de rua nas 27 capitais brasileiras-2003. São Paulo: SENAD / CEBRID; 2003.
11. Galduróz JC, Noto AR, Fonseca AM, Carlini EA. V levantamento nacional sobre o consumo de drogas psicotrópicas entre estudantes do ensino fundamental e médio da rede pública de ensino nas 27 capitais brasileiras (2004). São Paulo: SENAD/CEBRID; 2005. Available from: http://www.cebrid.epm.br.
12. Duailibi LB, Ribeiro M, Laranjeira R. Profile of cocaine and crack users in Brazil. Cad Saúde Pública. 2008;24:545-57.
13. Guindalini C, Vallada H, Breen B, Laranjeira R. Concurrent crack and powder cocaine users from São Paulo: do they represent a different group? BMC Public Health. 2006;6:10.
14. Oliveira LG, Nappo SA. Characterization of the crack cocaine culture in the city of the São Paulo: a controlled pattern of use. Rev Saúde Pública. 2008;42:664-71.
15. Malta M, Monteiro S, Lima RM, Bauken S, Marco A, Zuim GC, et al. HIV/AIDS risk among female sex workers who use crack in Southern Brazil. Rev Saúde Pública. 2008;42:830-7.
16. Carvalho HB, Seibel SD. Crack cocaine use and its relationship with violence and HIV. Clinics. 2009;64:857-66.
17. Dunn J, Laranjeira R, Silveira DX, Formigoni MLOS, Ferri CP. Crack cocaine: an increase in use among patients attending clinics in São Paulo: 1990-1993. Subst Use Misuse. 1996;31:519-27.
18. Derlet RW, Albertson TE. Emergency department presentation of cocaine intoxication. Ann Emerg Med. 1989;18:182-6.
19. Brody SL, Slovis CM, Wrenn KD. Cocaine-related medical problems: consecutive series of 233 patients. Am J Med. 1990;88:325-31.
20. Hamid A. Crack: new directions in drug research. Part 1. Differences between the marijuana economy and the cocaine/crack economy. Int J Addict. 1991;26:825-36.
21. Nappo SA, Galduróz JC, Noto AR. Uso do "crack" em São Paulo: fenômeno emergente? Rev ABP-APAL. 1994;16:75-83.
22. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Study to obtain comparable national estimates of problem drug use prevalence for all EU member states. Lisbon: EMCDDA; 2007. Available from: http://www.emcdda.europa.eu/attachements.cfm/att_44748_EN_TDSI07002ENC.pdf.
23. Ribeiro M, Dunn J, Sesso R, Lima M, Laranjeira R. Crack cocaine: a five year follow-up study of treated patients. Eur Addict Res. 2007;13:11-9.
24. Hser YI, Huang D, Brecht ML, Li L, Evans E. Contrasting trajectories of heroin, cocaine, and methamphetamine use. J Addict Dis. 2008;27:13-21.
25. Carlini EA, Galduróz JC, Silva AABS, Noto AR, Fonseca AM, Carlini CM, et al. II Levantamento domiciliar sobre o uso de drogas psicotrópicas no Brasil: estudo envolvendo as 108 maiores cidades do país. Brasília: SENAD/CEBRID; 2005. Available from: http://www.cebrid.epm.br.
26. Falck RS, Wang J, Carlson RG. Among long-term crack smokers, who avoids and who succumbs to cocaine addiction? Drug Alcohol Depend. 2008;98:24-9.
27. Gorelick DA. Progression of dependence in male cocaine addicts. Am J Drug Alcohol Abuse. 1992;18:13-9.
28. Chen K, Kandel D. Relationship between extent of cocaine use and dependence among adolescents and adults in the United States. Drug Alcohol Depend. 2002;68:65-85.
29. Chen CY, Anthony JC. Epidemiological estimates of risk in the process of becoming dependent upon cocaine: cocaine hydrochloride powder versus crack cocaine. Psychopharmacology (Berl). 2004;172:78-86.
30. Wagner FA, Anthony JC. Male-female differences in the risk of progression from first use to dependence upon cannabis, cocaine, and alcohol. Drug Alcohol Depend. 2007;86:191-8.
31. Werb D, Debeck K, Kerr T, Li K, Montaner J, Wood E. Modelling crack cocaine use trends over 10 years in a Canadian setting. Drug Alcohol Rev. 2010;29:271-7.
32. Confederação Nacional dos Municípios. Pesquisa sobre a situação do crack nos municípios brasileiros. Brasília: CNM; 2010. Available from: http://portal.cnm.org.br/sites/5700/5770/14122010 Mapeamento_ do Crack _nos_municipios_brasil_geral.pdf.
33. Schenker M, Minayo MCS. Fatores de risco e de proteção para o uso de drogas na adolescência. Ciência Saúde Col. 2005;10:707-17.
34. Paquette C, Roy E, Petit G, Boivin JF. Predictors of crack cocaine initiation among Montreal street youth: a first look at the phenomenon. Drug Alcohol Depend. 2010;110:85-91.
35. United Nations Organization. Adolescent substance use: risk and protection. New York: UNO; 2003.
36. Kliewer W, Murrelle L. Risk and protective factors for adolescent substance use: findings from a study in selected Central American countries. J Adolesc Health. 2007;40:448-55.
37. Rodríguez Funes GM, Brands B, Adlaf E, Giesbrecht N, Simich L, Wright Mda G. Factores de riesgo relacionados al uso de drogas ilegales: perspectiva crítica de familiares y personas cercanas en un centro de salud público en San Pedro Sula, Honduras. Rev Lat Am Enfermagem. 2009;17:796-802.
38. Beyers JM, Toumbourou JW, Catalano RF, Arthur MW, Hawkins JD. A cross-national comparison of risk and protective factors for adolescent substance use: the United States and Australia. J Adolesc Health. 2004;35:3-16.
39. Stronski SM, Ireland M, Michaud P, Narring F, Resnick MD. Protective correlates of stages in adolescent substance use: a Swiss National Study. J Adolesc Health. 2000;26:420-7.
40. Arthur MW, Hawkins JD, Pollard JA, Catalano RF, Baglioni AJ Jr. Measuring risk and protective factors for substance use, delinquency, and other adolescent problem behaviors. The communities that care youth survey. Eval Rev. 2002;26:575-601.
41. Haasen C, Prinzleve M, Zurhold H, Rehm J, Güttinger F, Fischer G, et al. Cocaine use in Europe: a multi-centre study. Methodology and prevalence estimates. Eur Addict Res. 2004;10:139-46.
42. Hatsukami DK, Fischman MW. Crack cocaine and cocaine hydrochloride. Are the differences myth or reality? JAMA. 1996;276:1580-8.
43. Oliveira LG, Nappo SA. Characterization of the crack cocaine culture in the city of São Paulo: a controlled pattern of use. Rev Saúde Pública. 2008;42:664-71.
44. Gawin FH. Cocaine addiction: psychology and neurophysiology. Science. 1991;251:1580-6.
45. Lowenstein DH, Massa SM, Rowbotham MC, Collins SD, McKinney HE, Simon RP. Acute neurologic and psychiatric complications associated with cocaine abuse. Am J Med. 1987;841-6.
46. Wetli CV, Fishbain DA. Cocaine-induced psycose and sudden death in recreational cocaine users. J Forensic Sci. 1985;30:873-80.
47. Haskell RM, Frankel HL, Rotondo MF. Agitation. AACN Clin Issues. 1997;8:335-50.
48. Boghdadi MS, Henning RJ. Cocaine: pathophysiology and clinical toxicology. Heart & Lung. 1997;26:466-83.
49. Stevens DC, Campbell JP, Carter JE, Watson WA. Acid-base abnormalities with cocaine toxicity in emergency department patients. Clin Toxicol.1994;32:31-9.
50. Hollander JE, Hoffman RS, Gennis P. Prospective multicenter evaluation of cocaine-associated chest paim. Acad Emerg Med. 1994;1:330-9.
51. Baumann BM, Perrone J, Horning SE, Shofer FS, Hollander JE. Cardiac and hemodynamic assessment of patients with cocaine-associated chest pain syndromes. Clin Toxicol Clin Toxicol. 2000;38:283-90.
52. Hollander JE, Hoffman RS, Gennis P. Cocaine associated chest pain: one-year followup. Acad Emerg Med. 1995;2:179-84.
53. Feldman JA, Fish SS, Beshanky JR, Griffith JL, Woolard RH, Selker HP. Acute cardiac ischemia in patients with cocaine-associated complaints: results of a multicenter trial. Ann Emerg Med. 2000;36:469-76.
54. Kaku DA, Lowenstein DH. Emergence of recreational drug abuse as major risk factor for stroke in young adults. Ann Intern Med. 1990;113:821-7.
55. Restrepo CS, Carrillo JA, Marti{dotless}nez S, Ojeda P, Rivera AL, Hatta A. Pulmonary complications from cocaine and cocaine based substances: Imaging manifestations. Radio Graphics. 2007;27:941-56.24.
56. Story A, Bothamley G, Hayward A. Crack cocaine and infectious tuberculosis. Emerg Infect Dis. 2008;14:1466-9.
57. National Treatment Agency for Substance Misuse. Models of care for the treatment of drug misusers. London: DH; 2002. Available from: http://www.nta.nhs.uk.
58. Shepard DS, Daley M, Ritter GA, Hodgkin D, Beinecke RH. Managed care and the quality of substance abuse treatment. J Ment Health Policy Econ. 2002;5:163-74.
59. Ford LK, Zarate P. Closing the gaps: the impact of inpatient detoxification and continuity of care on client outcomes. J Psychoactive Drugs. 2010;Suppl 6:303-14.
60. Edwards G, Gross MM. Alcohol dependence: provisional description of a clinical syndrome. Br Med J. 1976;1:1058-61.
61. Gawin FH, Kleber HD. Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Arch Gen Psychiatry. 1986;43:107-13.
62. Epstein DH, Preston KL. Daily life hour by hour, with and without cocaine: an ecological momentary assessment study. Psychopharmacol. 2010;211:223-32.
63. Negrete JC, Emil S. Cue-evoked arousal in cocaine users: a study of variance and predictive value. Drug Alcohol Depend. 1992;30:187-92.
64. Sofuoglu M, Dudish-Poulsen S, Brown SB, Hatsukami DK. Association of cocaine withdrawal symptoms with more severe dependence and enhanced subjective response to cocaine. Drug Alcohol Depend. 2003;69:273-82.
65. Razzouk D, Bordin IA, Jorge MR. Comorbidity and global functioning (DSM-III-R Axis V) in a Brazilian sample of cocaine users. Subst Use Misuse. 2000;35:1307-15.
66. Mulvaney FD, Alterman AI, Boardman CR, Kampman K. Cocaine abstinence symptomatology and treatment attrition. J Subst Abuse. Treat 1999;16:129-35.
67. Kampman KM. What's new in the treatment of cocaine addiction? Curr Psychiatry Rep. 2010;12:441-7.
68. Dackis CA. New treatments for cocaine abuse. Drug Disc Today Ther Strategies. 2005;2:79-86.
69. Pani PP, Trogu E, Vacca R, Amato L, Vecchi S, Davoli M. Disulfiram for the treatment of cocaine dependence. Cochrane Database Syst Rev. 2010;(1):CD007024.
70. Barth KS, Malcolm RJ. Disulfiram: an old therapeutic with new applications. CNS Neurol Disord Drug Targets. 2010;9:5-12.
71. Morgan PT, Pace-Schott E, Pittman B, Stickgold R, Malison RT. Normalizing effects of modafinil on sleep in chronic cocaine users. Am J Psychiatry. 2010;167:331-40.
72. Soares B, Lima Reisser AA, Farrell M, Silva de Lima M. Dopamine agonists for cocaine dependence. Cochrane Database Syst Rev. 2010;(2):CD003352.
73. Alvarez Y, Farré M, Fonseca F, Torrens M. Anticonvulsant drugs in cocaine dependence: a systematic review and meta-analysis. J Subst Abuse Treat. 2010;38:66-73.
74. Minozzi S, Amato L, Davoli M, Farrell M, Reisser RAL, Pani PP, et al. Anticonvulsants for cocaine dependence. Cochrane Database Syst Rev. 2010;(4):CD006754.
75. Kampman KM, Pettinati H, Lynch KG, Dackis C, Sparkman T, Weigley C. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend. 2004;75:233-40.
76. Martell BA, Orson FM, Poling J, Mitchell E, Rossen RD, Gardner T, et al. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry. 2009;66:1116-23.
77. Johnson BA. Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function. CNS Drugs. 2005;19:873-96.
78. Gorelick DA, Gardner EL, Xi ZX. Agents in development for the management of cocaine abuse. Drugs. 2004;64:1547-73.
79. Skinner MD, Coudert M, Berlin I, Passeri E, Michel L, Aubin HJ. Effect of the threat of a disulfiram-ethanol reaction on cue reactivity in alcoholics. Drug Alcohol Depend. 2010;112:239-46.
80. Jerônimo A, Meira C, Amaro A, Campello GC, Granja C. Choque cardiogê-nico por dissulfiram. Arq Bras Cardiol. 2009;92:43-5.
81. Karila L, Gorelick D, Weinstein A, Noble F, Benyamina A, Coscas S, et al. New treatments for cocaine dependence: a focused review. Int J Neuropsychopharmacol. 2008;11:425-38.
82. Castells X, Casas M, Pérez-Mañá C, Roncero C, Vidal X, Capellà D. Efficacy of psychostimulant drugs for cocaine dependence. Cochrane Database Syst Rev. 2010;(2):CD007380.
83. Carlson RG, Sexton R, Wang J, Falck R, Leukefeld CG, Booth BM. Predictors of substance abuse treatment entry among rural illicit stimulant users in Ohio, Arkansas, and Kentucky. Subst Abus. 2010;31:1-7.
84. Metsch LR, McCoy HV, McCoy CB, Miles CC, Edlin BR, Pereyra M. Use of health care services by women who use crack cocaine. Women Health. 1999;30:35-51.
85. Dias AC, Ribeiro M, Dunn J, Sesso R, Laranjeira R. Follow-up study of crack cocaine users: situation of the patients after 2, 5, and 12 years. Subst Abuse. 2008;29:71-9.
86. Falck RS, Wang J, Siegal HA, Carlson RG. The prevalence of psychiatric disorder among a community sample of crack cocaine users: an exploratory study with practical implications. J Nerv Ment Dis. 2004;192:503-7.
87. Dunn J, Laranjeira R. Desenvolvimento de entrevista estruturada para avaliar consumo de cocaína e comportamentos de risco. Rev Bras Psiquiatr. 2000;22:11-6.
88. Gottheil E, Weinstein SP, Sterling RC, Lundy A, Serota RD. A randomized controlled study of the effectiveness of intensive outpatient treatment for cocaine dependence. Psychiatr Serv. 1998;49:782-7.
89. Agosti V, Nunes E, Ocepeck-Welikson K. Patient factors related to early attrition from an outpatient cocaine research clinic. Am J Drug Alcohol Abuse. 1996;22:29-39.
90. National Treatment Agency for Susbtance Misuse. Models of care for the treatment of adult drug misusers-update 2006. London: DH; 2006. Available from: http://www.nta.nhs.uk.
91. Malbergier A. Trantornos psiquiátricos em usuários de drogas injetáveis infectados pelo HIV. J Bras Psiq. 1998;48:253-62.
92. Haasen C, Prinzleve M, Gossop M, Fischer G, Casas M. Relationship between cocaine use and mental health problems in a sample of European cocaine powder or crack users. World Psychiatry. 2005;4:173-6.
93. Herbeck DM, Hser YI, Lu AT, Stark ME, Paredes A. A 12-year follow-up study of psychiatric symptomatology among cocaine-dependent men. Addict Behav. 2006;31:1974-87.
94. Herrero MJ, Domingo-Salvany A, Torrens M, Brugal MT; Itinere Investigators. Psychiatric comorbidity in young cocaine users: induced versus independent disorders. Addiction. 2008;103:284-93.
95. Rosenblum A, Fallon B, Magura S, Handelsman L, Foote J, Bernstein D. The autonomy of mood disorders among cocaine-using methadone patients. Am J Drug Alcohol Abuse. 1999;25:67-80.
96. Schönnesson LN, Williams M, Atkinson J, Timpson S. Factors associated with depressive symptoms in African American crack cocaine smokers. J Subst Use. 2009;14:161-74.
97. Vogenthaler NS, Hadley C, Rodriguez AE, Valverde EE, Del Rio C, Metsch LR. Depressive symptoms and food insufficiency among HIV-infected crack users in Atlanta and Miami. AIDS Behav. 2011;15(7):1520-6.
98. Zubaran C, Foresti K, Thorell MR, Franceschini P, Homero W. Depressive symptoms in crack and inhalant users in Southern Brazil. J Ethn Subst Abuse. 2010;9:221-36.
99. Carroll KM, Rounsaville BJ, Bryant KJ. Alcoholism in treatment-seeking cocaine abusers: clinical and prognostic significance. J Stud Alcohol. 1993;54:199-208.
100. Rubio G, Manzanares J, Jiménez M, Rodríguez-Jiménez R, Martínez I, Iribarren MM, et al. Use of cocaine by heavy drinkers increases vulnerability to developing alcohol dependence: a 4-year follow-up study. J Clin Psychiatry. 2008;69:563-70.
101. Harris DS, Everhart ET, Mendelson J, Jones RT. The pharmacology of cocaethylene in humans following cocaine and ethanol administration. Drug Alcohol Depend. 2003;72:169-82.
102. Oliveira LG, Ponce JC, Nappo SA. Crack cocaine use in Barcelona: a reason of worry. Subst Use Misuse. 2010;45:2291-300.
103. Oliveira LG, Nappo SA. Characterization of the crack cocaine in the city of the São Paulo: a controlled pattern of use. Rev Saúde Pública. 2008;42:664-71.
104. Prinzleve M, Haasen C, Zurhold H, Matali JL, Bruguera E, Gerevich J, et al. Cocaine use in Europe: a multi-centre study: patterns of use in different groups. Eur Addict Res. 2004;10:147-55.
105. Stinson FS, Grant BF, Dawson DA, Ruan WJ, Huang B, Saha T. Comorbidity between DSM-IV alcohol and specific drug use disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend. 2005;80:105-16.
106. Tang Y, Kranzler H, Gelernter J, Farrer LA, Cubells JF. Comorbid psychiatric diagnoses and their association with cocaine-induced psychosis In cocaine-dependent subjects. Am J Addict. 2007;16:343-51.
107. Crawford V, Crome JB, Clancy C. Coexisting problems of mental health and substance misuse (dual diagnosis): a literature review. Drugs: Education, Prevention and Policy. 2003;10(Suppl):S1-74.
108. Los Cobos JP, Siñol N, Bañulus E, Batlle F, Tejero A, Trujols J. Personality traits of cocaine-dependent patients associated with cocaine-positive baseline urine at hospitalization. Am J Drug Alcohol Abuse. 2010;36:52-6.
109. Weinstock J, Rash CJ, Petry NM. Contingency management for cocaine use in methadone maintenance patients: when does abstinence happen? Psychol Addict Behav. 2010;24:282-91.
110. Stitzer ML, Petry N, Peirce J, Kirby K, Killeen T, Roll J, et al. Effectiveness of abstinence-based incentives: interaction with intake stimulant test results. J Consult Clin Psychol. 2007;75:805-11.
111. Caplan AL. Ethical issues surrounding forced, mandated, or coerced treatment. J Subst Abuse Treat. 2006;31:117-20.
112. Moeller KE, Lee KC, Kissack JC. Urine drug screening: practical guide for clinicians. Mayo Clin Proc. 2008;83:66-76.
113. Moller M, Gareri J, Koren G. A review of substance abuse monitoring in a social services context: a primer for child protection workers. Can J Clin Pharmacol. 2010;17:e177-93.
114. Krasowski MD, Pizon AF, Siam MG, Giannoutsos S, Iyer M, Ekins S. Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine. BMC Emerg Med. 2009;28:9:5.
115. Cone EJ, Sampson-Cone AH, Darwin WD, Huestis MA, Oyler JM. Urine testing for cocaine abuse: metabolic and excretion patterns following different routes of administration and methods for detection of false-negative results. J Anal Toxicol. 2003;27:386-401.
116. Preston KL, Huestis MA, Wong CJ, Umbricht A, Goldberger BA, Cone EJ. Monitoring cocaine use in substance-abusetreatment patients by sweat and urine testing. J Anal Toxicol. 1999;23:313-22.
117. Klein J, Karaskov T, Koren G. Clinical applications of hair testing for drugs of abuse: the Canadian experience. Forensic Sci Int. 2000;107:281-8.
118. Spiehler V. Hair analysis by immunological methods from the beginning to 2000. Forensic Sci Int. 2000;107:249-59.
119. Moore C, Deitermann D, Lewis D, Feeley B, Niedbala RS. The detection of cocaine in hair specimens using microplate enzyme immunoassay. J Forensic. Sci 1999;44:609-12.
120. Garcia-Bournissen F, Moller M, Nesterenko M, Karaskov T, Koren G. Pharmacokinetics of disappearance of cocaine from hair after discontinuation of drug use. Forensic Sci Int. 2009;189:24-7.
121. London ED, Bonson KR, Ernst M, Grant S. Brain imaging studies of cocaine abuse: implications for medication development. Crit Rev Neurobiol. 1999;13:227-42.
122. Verdejo-García A, Pérez-García M, Sánchez-Barrera M, Rodriguez-Fernández A, Gómez-Río M. Neuroimaging and drug addiction: neuroanatomical correlates of cocaine, opiates, cannabis and ecstasy abuse. Rev Neurol. 2007;44:432-9.
123. Gosseries O, Demertzi A, Noirhomme Q, Tshibanda J, Boly M, Beeck MO, et al. Functional neuroimaging (fMRI, PET and MEG): what do we measure? Rev Med Liege. 2008;63:231-7.
124. Kilts CD, Schweitzer JB, Quinn CK, Gross RE, Faber TL, Muhammad F, et al. Neural activity related to drug craving in cocaine addiction. Arch Gen Psychiatry. 2001;58:334-41.
125. Kilts CD, Gross RE, Ely TD, Drexler KP. The neural correlates of cue-induced craving in cocaine-dependent women. Am J Psychiatry. 2004;161:233-41.
126. Volkow ND, Fowler JS, Wang GJ, Telang F, Logan J, Jayne M, et al. Cognitive control of drug craving inhibits brain reward regions in cocaine abusers. Neuroimage. 2010;49:2536-43.
127. Cook JA. Associations between use of crack cocaine and HIV-1 disease progression: research findings and implications for mother-to-infant transmission. Life Science. 2011;88:931-9.
128. Bauer CR, Langer JC, Shankaran S, Bada HS, Lester B, Wright LL, et al. Acute neonatal effects of cocaine exposure during pregnancy. Arch Pediatr Adolesc Med. 2005;159:824-34.
129. Schiller C, Allen PJ. Follow-up of infants prenatally exposed to cocaine. Pediatr Nurs. 2005;31:427-36.
130. Curet LB, His AC. Drug abuse during pregnancy. Clinical Obstet Ginecol. 2002;45:73-88.
131. Haasen C, Krausz M. Myths versus evidence with respect to cocaine and crack: learning from the US experience. Eur Addict Res. 2001;7:159-60.
132. Eyler FD, Behnke M, Conlon M, Woods NS, Wobie K. Birth outcome from a prospective, matched study of prenatal crack/cocaine use: I. Interactive and dose effects on health and growth. Pediatrics. 1998;101:229-37.
133. Richardson GA, Hamel SC, Goldschmidt L, Day NL. Growth of infants prenatally exposed to cocaine/crack: comparison of a prenatal care and a no prenatal care sample. Pediatrics. 1999;104:e18.
134. van Huis M, van Kempen AA, Peelen M, Timmers M, Boer K, Smit BJ, et al. Brain ultrasonography findings in neonates with exposure to cocaine during pregnancy. Pediatr Radiol. 2009;39:232-8.
135. Chiriboga CA, Kuhn L, Wasserman GA. Prenatal cocaine exposures and dose-related cocaine effects on infant tone and behavior. Neurotoxicol Teratol. 2007;29:323-30.
136. Bada HS, Das A, Bauer CR, Shankaran S, Lester B, LaGasse L, et al. Impact of prenatal cocaine exposure on child behavior problems through school age. Pediatrics. 2007;119:e348-59.
137. Frank DA, Jacobs RR, Beeghly M, Augustyn M, Bellinger D, Cabral H, et al. Level of prenatal cocaine exposure and scores on the Bayley scales of infant development: modifying effects of caregiver, early intervention, and birth weight. Pediatrics. 2002;110:1143-52.
138. Scher MS, Richardson GA, Day NL. Effects of prenatal cocaine/crack and other drug exposure on electroencephalographic sleep studies at birth and one year. Pediatrics. 2000;105:39-48.
139. Messinger DS, Bauer CR, Das A, Seifer R, Lester BM, Lagasse LL, et al. The maternal lifestyle study: cognitive, motor, and behavioral outcomes of cocaine-exposed and opiate-exposed infants through three years of age. Pediatrics. 2004;113:1677-85.
140. Ackerman JP, Riggins T, Black MM. A review of the effects of prenatal cocaine exposure among school-aged children. Pediatrics. 2010;125:554-65.
141. Frank DA, Augustyn M, Knight WG, Pell T, Zuckerman B. Growth, development, and behavior in early childhood following prenatal cocaine exposure: a systematic review. JAMA. 2001;285:1613-25.
142. Hurt H, Betancourt LM, Malmud EK, Shera DM, Giannetta JM, Brodsky NL, et al. Children with and without gestational cocaine exposure: a neurocognitive systems analysis. Neurotoxicol Teratol. 2009;31:334-41.
143. Behnke M, Eyler FD, Garvan CW, Wobie K, Hou W. Cocaine exposure and developmental outcome from birth to 6 months. Neurotoxicol Teratol. 2002;24:283-95.
144. Mayes LC, Granger RH, Frank MA. Neurobehavioral profiles of neonates exposed to cocaine prenataly. Pediatrics. 1993;91:778-3.
145. Eyler FD, Behnke M, Garvan CW, Woods NS, Wobie K, Conlon M. Newborn evaluations of toxicity and withdrawal related to prenatal cocaine exposure. Neurotoxicol Teratol. 2001;23:399-411.
146. Ogunyemi D, Hernández-Loera GE. The impact of antenatal cocaine use on maternal characteristics and neonatal outcomes. J Matern Fetal Neonatal Med. 2004;15:253-9.
147. Covington CY, Nordstrom-Klee B, Ager J, Sokol R, Delaney-Black V. Birth to age 7 growth of children prenatally exposed to drugs: a prospective cohort study. Neurotoxicol Teratol. 2002;24:489-96.
148. Richardson GA, Goldschmidt L, Larkby C. Effects of prenatal cocaine exposure on growth: a longitudinal analysis. Pediatrics. 2007;120:e1017-27.
149. Singer LT, Minnes S, Short E, Arendt R, Farkas K, Lewis B, et al. Cognitive outcomes of preschool children with prenatal cocaine exposure. JAMA. 2004;291:2448-56.
150. Chiriboga CA, Starr D, Kuhn L, Wasserman GA. Prenatal cocaine exposure and prolonged focus attention. Poor infant information processing ability or precocious maturation of attentional systems? Dev Neurosci. 2009;31:149-58.
151. Morrow CE, Bandstra ES, Anthony JC, Ofir AY, Xue L, Reyes MB. Influence of prenatal cocaine exposure on early language development: longitudinal findings from four months to three years of age. J Dev Behav Pediatr. 2003;24:39-50.
152. Bandstra ES, Vogel AL, Morrow CE, Xue L, Anthony JC. Severity of prenatal cocaine exposure and child language functioning through age seven years: a longitudinal latent growth curve analysis. Subst Use Misuse. 2004;39:25-59.
153. Singer LT, Arendt R, Minnes S, Farkas K, Salvator A, Kirchner HL, et al. Cognitive and motor outcomes of cocaine-exposed infants. JAMA. 2002;287:1952-60.
154. Lohoff FW, Bloch PJ, Weller AE, Nall AH, Doyle GA, Buono RJ, et al. Genetic variants in the cocaine-and amphetamine regulated transcript gene (CARTPT) and cocaine dependence. Neurosci Lett. 2008;440:280-3.
155. Li MD, Burmeister M. New insights into the genetics of addiction. Nat Rev Genet. 2009;10:225-31.
156. Tsuang MT, Lyons MJ, Eisen SA, Goldberg J, True W, Lin N, et al. Genetic influences on DSM-III-R drug abuse and dependence: a study of 3,372 twin pairs. Am J Med Genet. 1996;67:473-7.
157. Caster JM, Kuhn CM. Maturation of coordinated immediate early gene expression by cocaine during adolescence. Neuroscience. 2009;160:13-31.
158. Gourley SL, Koleske AJ, Taylor JR. Loss of dendrite stabilization by the Abl-related gene (Arg) kinase regulates behavioral flexibility and sensitivity to cocaine. Proc Natl Acad Sci USA. 2009;106:16859-64.
159. Kreek MJ, Nielsen DA, Butelman ER, LaForge KS. Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neurosci. 2005;8:1450-7.
160. Flagel SB, Robinson TE, Clark JJ, Clinton SM, Watson SJ, Seeman P, et al. An animal model of genetic vulnerability to behavioral disinhibition and responsiveness to reward-related cues: implications for addiction. Neuropsychopharmacology. 2010;35:388-400.
161. Thompson D, Martini L, Whistler JL. Altered ratio of D1 and D2 dopamine receptors in mouse striatum is associated with behavioral sensitization to cocaine. PLoS One. 2010;5:e11038.
162. Gaval-Cruz M, Weinshenker D. Mechanisms of disulfiram-induced cocaine abstinence: antabuse and cocaine relapse. Mol Interv. 2009;9:175-87.
163. Bierut LJ, Dinwiddie SH, Begleiter H, Crowe RR, Hesselbrock V, Nurnberger JI Jr, et al. Familial transmission of substance dependence: alcohol, marijuana, cocaine, and habitual smoking: a report from the Collaborative Study on the Genetics of Alcoholism. Arch Gen Psychiatry. 1998;55:982-8.